GCM
EW icon

Genus Capital Management’s Edwards Lifesciences EW Stock Holding History

Genus Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,940
Closed -$1.71M – 196
2024
Q3 		$1.71M Sell
25,940
-97,359
-79% -$7.07M 0.22% 103
2024
Q2 		$11.4M Buy
+123,299
New +$10.9M 1.5% 13
2024
Q1 		– Sell
-64,900
Closed -$4.95M – 265
2023
Q4 		$4.95M Buy
+64,900
New +$4.52M 0.73% 43

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Genus Capital Management's EW Position: Q2 2024 in Review

Genus Capital Management sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 119,929 shares — an estimated $10.6M sold.

Genus Capital Management first reported a position in EW in Q1 2024 and held it in 1 quarter. The position peaked at $11.5M in Q1 2024. 1,296 funds tracked by Wall St. Rank hold EW as of Q2 2024.

  • Genus Capital Management reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
  • Genus Capital Management sold 119,929 Edwards Lifesciences shares in Q2 2024, an estimated $10.6M.
  • Genus Capital Management first reported a position in Edwards Lifesciences in Q1 2024 and held it in 1 quarter.
  • Genus Capital Management's Edwards Lifesciences position peaked at $11.5M in Q1 2024.
  • 1,296 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on Genus Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.